Physician profile
Douglas Slaughter
NPI 1194773911
$101,076.26
in general payments reported to CMS, 2019-2025
23 companies · $6,363 in 2025
The $6,363 reported for 2025 was more than what a typical Orthopaedic Surgery of The Spine provider received nationally (typical 2025 total: $2,116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $19K · 2021: $15K · 2022: $13K · 2023: $6,542 · 2024: $17K · 2025: $6,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $23K · Travel and Lodging: $4,449 · Food and Beverage: $1,607 · Consulting Fee: $1,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $22,670.39 |
| Travel and Lodging | $4,448.52 |
| Food and Beverage | $1,606.97 |
| Consulting Fee | $1,575.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innosys Medical Technologies. INC. | $36,512.88 | 2019-2022 | |
| Choice Spine, LLC | $35,184.64 | 2019-2025 | Tigershark M, Triton, Veo Lateral Interbody Fusion System |
| Cg Medtech USA, INC | $12,403.94 | 2024 | Anax Oct |
| Spineart USA INC | $5,776.94 | 2020-2023 | Perla C, Perla Tl |
| Spine Wave, INC. | $5,302.39 | 2019 | |
| Centinel Spine, LLC | $3,198.28 | 2019-2020 | |
| Cerapedics INC. | $1,500.00 | 2019 | |
| Si-Bone, INC. | $474.34 | 2019-2020 | |
| Republic Spine | $191.62 | 2021 | |
| Genzyme Corporation | $134.58 | 2024 | |
| Highridge Medical LLC | $59.64 | 2025 | Biomet Spinalpak Non-Invasive Spine Fusion Stimulator System |
| Ebi, LLC | $59.64 | 2025 | Biomet Spinalpak Non-Invasive Spine Fusion Stimulator System |
| Pacira Pharmaceuticals Incorporated | $38.49 | 2022-2024 | Exparel, Iovera, Zilretta |
| Zimvie INC. | $37.83 | 2023-2024 | |
| Relievant Medsystems, INC. | $35.49 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intrinsic Therapeutics | $32.44 | 2021 | |
| Spinal Elements, INC. | $32.17 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $20.12 | 2023 | Seglentis |
| Reel Surgical, INC. | $19.67 | 2024 | |
| Abbott Laboratories | $16.60 | 2023 | Proclaim |
| Vertex Pharmaceuticals Incorporated | $16.03 | 2024 | |
| Nuvasive, INC. | $15.21 | 2022 | |
| Curonix LLC | $13.32 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$15,236.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Slaughter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.